BiPar Sciences Inc.
Division of Sanofi
Latest From BiPar Sciences Inc.
AntriaBio, a biopharmaceutical company focused on developing treatments for diabetes and metabolic diseases, has named Dr Barry Sherman to its board of directors. Notably, Dr Sherman was the first chief medical officer of Genentech in the mid-1990s following his role directing Genentech's clinical research and medical affairs teams. He has also served as president and CEO of StemPar Sciences, president and CEO of Anergen Inc, a founder of Pain Therapeutics, and the executive vice-president and co-founder of BiPar Sciences.
The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.
Late-stage data on Sanofi pipeline drugs potentially worth more than €4 billion in annual sales are accumulating, and the next six months will be critical. There are five key Phase III read-outs due by the end of the third quarter, meaning that by October the French firm's mid-term growth potential could look a lot clearer.
CytomX Therapeutics, a biotechnology company developing monoclonal antibody therapies, has appointed Dr Hoyoung Huh chair of the board of directors. Dr Huh currently serves as chair of Geron Corporation, and on the boards of Addex Pharmaceuticals and BayBio. He was previously CEO, president and chair of BiPar Sciences, which was acquired by Sanofi in 2009. Former CytomX chair Dr Charles Homcy, venture partner at Third Rock Ventures, will continue to serve on the board.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
Atul Dhir, MD, PhD, CEO
Charles Bradley, PhD, VP, Clinical Dev.
- Contact Info
BiPar Sciences Inc.
Phone: (650) 635-6050
1000 Marina Blvd.
Brisbane, CA 94005
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.